QLT, Inc. (NASDAQ: QLTI), a global biopharmaceutical company, has dedicated their efforts to discovering, developing and commercializing novel therapies. The company’s research and development efforts are focused on the field of ophthalmology. QLT leverages its three unique technology platforms, photodynamic therapy, Atrigel® and punctal plugs with drugs, to develop products such as Visudyne® and Eligard® and future product opportunities. For further information, visit the Company’s web site at www.qltinc.com.
- 17 years ago
QualityStocks
QLT, Inc. (NASDAQ: QLTI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France
VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…
-
QualityStocksNewsBreaks – Brand Engagement Network Inc. (NASDAQ: BNAI) Reports Warrant Exercises, Debt Conversion, and Public Warrants Update
Brand Engagement Network Inc. (NASDAQ: BNAI) announced on Wednesday that it generated approximately $1.46 million…
-
Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape
The World Health Organization’s recent recognition of rare diseases as a global health priority underscores…